What are the ACOG recommendations for low‑dose aspirin use to prevent preeclampsia in pregnant women at increased risk, including dosage, timing, and contraindications?

ACOG Guidelines on Aspirin Use for Preeclampsia Prevention

ACOG recommends low-dose aspirin 81 mg daily for pregnant women at high risk of preeclampsia, initiated between 12-28 weeks of gestation (optimally before 16 weeks) and continued until delivery, though emerging evidence suggests doses of 100-150 mg may be more effective for certain high-risk populations. 1, 2

High-Risk Factors Requiring Aspirin Prophylaxis

ACOG defines high-risk women as those with one or more of the following conditions 1, 2:

• History of preeclampsia, especially early-onset preeclampsia with delivery <34 weeks 1, 2
• Multifetal gestation (twins or higher-order multiples) 1, 2
• Chronic hypertension 1, 2
• Type 1 or type 2 diabetes mellitus 1, 2
• Renal disease 1, 2
• Autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome) 1, 2

Moderate-Risk Factors

ACOG recommends considering aspirin prophylaxis for women with more than one of the following moderate-risk factors 1, 2:

• First pregnancy (nulliparity) 1, 2
• Maternal age ≥35 years 1, 2
• Body mass index >30 kg/m² 1, 2
• Family history of preeclampsia 1, 2
• Low socioeconomic status 1, 2
• Personal history factors (prior adverse pregnancy outcomes) 1, 2

Dosing Recommendations

Standard ACOG Dosing

ACOG recommends 81 mg daily as the standard prophylactic dose 1, 2. This recommendation is based on the most commonly available formulation in the United States and established safety data 3.

Emerging Evidence for Higher Dosing

However, critical evidence suggests that the standard 81 mg dose may be suboptimal, particularly for certain high-risk populations 4, 5:

• Doses >100 mg initiated before 16 weeks are significantly more effective than lower doses, with a risk reduction of RR 0.33 (95% CI 0.19-0.57, p<0.0001) for preeclampsia 4
• International guidelines increasingly recommend 150 mg daily, including the Royal College of Obstetricians and Gynaecologists, International Federation of Gynecology and Obstetrics (FIGO), and German guidelines 4, 5

Specific Populations Requiring Higher Doses (100-150 mg daily)

Chronic hypertension: The standard 81 mg dose has been shown to be ineffective in women with chronic hypertension. A study of 457 women demonstrated no reduction in superimposed preeclampsia (34.3% without aspirin vs 35.5% with 81 mg aspirin, p=0.79), and severe features actually increased (21.7% vs 31.0%, p=0.03) 6, 4. Consider 100-150 mg daily for this population 4.

Diabetes mellitus: The American Diabetes Association specifically recommends 100-150 mg daily for pregnant women with type 1 or type 2 diabetes 4.

Morbid obesity (BMI >40 kg/m²): Women with higher BMI have increased platelet turnover and reduced aspirin absorption, requiring 100-150 mg daily to achieve adequate platelet inhibition 4.

Multifetal gestation: Higher dosing (100-150 mg daily) should be considered for twin or higher-order pregnancies 4.

Timing of Initiation

Initiate aspirin between 12-16 weeks of gestation for maximum effectiveness 1, 2. The window extends up to 28 weeks, but efficacy decreases with later initiation 1, 2.

Rationale for Early Timing

• Defective placentation and inadequate spiral artery remodeling occur in the first trimester 4
• Aspirin initiated early can improve uteroplacental blood flow during the critical period of placentation 4
• Evidence suggests that initiation before 16 weeks is significantly more effective than later initiation 4, 5, 7

Preconception Initiation

Preconception initiation is safe and may be beneficial, particularly for women with chronic conditions affecting placentation (chronic hypertension, diabetes, autoimmune disease, renal disease) 4, 8.

Duration of Therapy

Continue aspirin daily until delivery 1, 2. Do not stop at 36 weeks, as this removes protection during a high-risk period without evidence-based rationale 4.

Key Points on Duration

• Preeclampsia risk persists throughout pregnancy and into the early postpartum period 4
• Eclamptic seizures can develop for the first time after delivery 4
• Low-dose aspirin (75-81 mg) does not increase risks of placental abruption, postpartum hemorrhage, or fetal intracranial bleeding when continued until delivery 4, 3

Exception for Planned Cesarean with Neuraxial Anesthesia

If a scheduled cesarean section with spinal anesthesia is planned, consider discontinuing aspirin 7-10 days before the procedure to allow adequate platelet recovery, and verify platelet count >75 × 10⁹/L immediately before spinal anesthesia 9. However, this is not routinely necessary for low-dose aspirin.

Safety Profile

Low-dose aspirin is safe throughout pregnancy and does not increase the risk of 3, 1, 2:

• Placental abruption
• Postpartum hemorrhage
• Fetal intracranial bleeding
• Perinatal mortality
• Congenital anomalies
• Cesarean delivery rates

Expected Benefits

When used in high-risk women, low-dose aspirin provides 3:

• 24% reduction in preeclampsia risk (absolute risk reduction 2-5%, NNT=42)
• 14% reduction in preterm birth
• 20% reduction in intrauterine growth restriction
• Increase in mean birthweight by approximately 130g

Special Populations

Antiphospholipid Syndrome

For women with antiphospholipid syndrome, combine low-dose aspirin (81-100 mg daily) with prophylactic-dose low-molecular-weight heparin (LMWH) starting in the first trimester 4. Add hydroxychloroquine to improve pregnancy outcomes 4.

Systemic Lupus Erythematosus

Women with SLE should receive low-dose aspirin starting in the first trimester plus hydroxychloroquine throughout pregnancy to reduce disease activity and preeclampsia risk 4.

Recurrent Pregnancy Loss

Women with a history of recurrent pregnancy loss benefit from aspirin prophylaxis, particularly when combined with other risk factors 4.

Common Pitfalls to Avoid

1. Do not confuse low-dose aspirin (75-162 mg) with high-dose aspirin (>100 mg for analgesia). The FDA warning about aspirin in the third trimester refers to high doses, not prophylactic low doses 4.

2. Do not stop aspirin at 36 weeks "just to be safe"—this removes protection during a high-risk period 4.

3. Do not underdose women with chronic hypertension, diabetes, or morbid obesity—these populations may require 100-150 mg daily rather than the standard 81 mg 4.

4. Do not delay initiation beyond 16 weeks if possible, as early initiation is critical for optimal effectiveness 4, 5, 7.

5. Do not use aspirin for prevention of early pregnancy loss, fetal growth restriction, stillbirth, or preterm birth in the absence of high-risk factors for preeclampsia—current evidence does not support this 1, 2.

Contraindications

While ACOG guidelines do not explicitly list absolute contraindications, use clinical judgment in women with:

• Active bleeding disorders
• Severe thrombocytopenia
• Known aspirin allergy or hypersensitivity
• Active peptic ulcer disease

Formulation Considerations

Either regular or enteric-coated aspirin is acceptable 4. Enteric-coated formulations may reduce minor gastrointestinal side effects 4. Both chewable and pill formulations have the same safety profile 4.

Clinical Implementation Algorithm

1. Identify high-risk factors at the first prenatal visit (ideally <12 weeks)
2. Prescribe aspirin between 12-16 weeks (optimally before 16 weeks)
3. Choose dose based on risk profile:
   • Standard risk: 81 mg daily
   • Chronic hypertension, diabetes, BMI >40, or multifetal gestation: Consider 100-150 mg daily
4. Continue daily until delivery (do not stop at 36 weeks)
5. Counsel on safety: No increased bleeding risk, safe throughout pregnancy